Regeneron Pharmaceuticals Shares Rise Following Q3 Revenue Beat
Regeneron Pharmaceuticals (REGN) saw a rise in premarket trading following the release of third-quarter results that exceeded analyst expectations. The company reported significant year-over-year revenue growth of approximately 36%, largely propelled by its ongoing collaboration with Sanofi regarding Eylea. The strong financial performance highlights the success of Regeneron's key product portfolio and strategic partnerships. This growth provides positive momentum for the New York-based pharmaceutical giant as it continues to expand its market presence in the biotech sector.
